Join us for our live virtual event Biotech’s New Normal: Challenges and Opportunities. Our journalists will discuss the emerging biotech ecosystem with executives, venture investors and industry experts, building on our award-winning coverage of the sector. Register for free here: https://lnkd.in/eDTkbkJK
BioPharma Dive
在线音视频媒体
Washington，District of Columbia 14,744 位关注者
We provide business journalism and in-depth insight into the most impactful news and trends shaping biotech and pharma
关于我们
BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 13+ million decision-makers in the most competitive industries.
- 网站
-
https://www.biopharmadive.com
BioPharma Dive的外部链接
- 所属行业
- 在线音视频媒体
- 规模
- 201-500 人
- 总部
- Washington，District of Columbia
动态
-
The amount surpassed the European firm’s targets, allowing it to increase the size and number of company financings it plans to do in the future. #funding #lifesciences
-
#Biosimilar competition is expected in early January for the Johnson & Johnson's second highest-selling drug, putting greater focus on newer products' market trajectory. #pharma
Tremfya, Carvykti sales grow as J&J prepares for Stelara patent loss
biopharmadive.com
-
Join the editorial team at BioPharma Dive for a live virtual event on November 13 where you will get the full spectrum on the state of biotech companies today, from the private and public financing landscape, to the construction and strategy of the companies, and the new momentum building in therapeutic areas like immunology and neuroscience. Register for free now: https://lnkd.in/gQjau6vF #Biotech #Pharmaceuticals #ClinicalResearch #DrugDevelopment #LifeSciences
-
-
The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling medicines, Zepbound and Mounjaro, while it reevaluates its recent decision to declare the drugs back in supply. #pharma
FDA, facing pressure, to review position on Zepbound, Mounjaro shortage
biopharmadive.com
-
The deal would hand Lundbeck a?treatment for a series of rare brain disorders that could, by the company's estimates, become a blockbuster product. #Biopharma
Lundbeck to buy brain drug developer Longboard for $2.6B
biopharmadive.com
-
The offering will fund the #biotech's testing of a potential rival to Amgen’s?Tezspire and?is already the sixth for an immune drug developer this year, the most since 2021. #IPO
Upstream prices $255M IPO in bid to challenge Amgen, AstraZeneca asthma drug
biopharmadive.com
-
The French #pharmaceutical giant Sanofi said it’s in negotiations to sell a controlling stake of Opella to the private equity firm CD&R, in a deal that reportedly could be worth more than $16 billion.
Sanofi may have found a buyer for its consumer health business
biopharmadive.com
-
Seven young boys given Bluebird's Skysona later developed blood cancers, findings that could shape how doctors balance the #genetherapy’s risks against its benefit. #biopharma
New data underline cancer risk of Bluebird therapy for brain disease
biopharmadive.com
-
Data readouts over the next six months could set expectations for how the highly lucrative market for #weightloss therapies will look in the future.?#pharma
Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch.
biopharmadive.com